|
25 Oct 2019 |
FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy
|
|
21 Oct 2019 |
OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
|
|
17 Oct 2019 |
Horizon Therapeutics plc Initiates PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) to Improve Management of Uncontrolled Gout for Adults with a Kidney Transplant
|
|
16 Oct 2019 |
Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival
|
|
16 Oct 2019 |
Nektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
|
|
16 Oct 2019 |
Aro Biotherapeutics Debuts Lead Centyrin Candidate at 2019 OTS Meeting
|
|
15 Oct 2019 |
AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
|
|
14 Oct 2019 |
DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease
|
|
12 Oct 2019 |
Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration
|
|
10 Oct 2019 |
Galderma Announces Positive Phase 2 Results for its Proprietary Liquid Formulation of an Investigational Botulinum Toxin and Approval of New State-of-the-Art Manufacturing Facility
|
|
08 Oct 2019 |
FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder
|
|
08 Oct 2019 |
FDA Approves Octapharma’s WILATE® for Hemophilia A in Adult and Adolescent Patients
|
|
08 Oct 2019 |
Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis
|
|
08 Oct 2019 |
Intarcia Therapeutics Provides Regulatory Update - FDA Accepts Resubmitted New Drug Application For ITCA 650
|
|
08 Oct 2019 |
Stealth BioTherapeutics Presents Data on SBT-272 in Neurodegeneration
|
|
08 Oct 2019 |
Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis
|
|
08 Oct 2019 |
Axcella Provides Progress Updates for Liver Program Candidates AXA1125 and AXA1957
|
|
03 Oct 2019 |
Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor-Localized Immunotherapy
|
|
02 Oct 2019 |
Ra Pharmaceuticals Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for gMG
|
|
02 Oct 2019 |
Evolus Receives Approval for Nuceiva™ in the European Union
|
|
01 Oct 2019 |
TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic Cancer
|
|
01 Oct 2019 |
Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 for HPV16-driven Head and Neck Squamous Cell Carcinoma
|
|
29 Sep 2019 |
Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Malignant Ascites
|
|
29 Sep 2019 |
Bicycle Therapeutics Announces Presentation of Updated Data from Phase I/IIa Trial Evaluating BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress
|
|
27 Sep 2019 |
89bio Announces Dosing of First Patients in NASH Study and Issuance of Composition of Matter Patent
|
